A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration
Timothy L. Jackson,Jason Slakter,Marc Buyse,Kun Wang,Pravin U. Dugel,Charles C. Wykoff,David S. Boyer,Michael Gerometta,Megan E. Baldwin,Clare F. Price,Bohdan Kousal,Jan Studnicka,Michal Veith,Catherine Creuzot-Garcher,Flore De Bats,David Gaucher,Martine Mauget-Faysse,Eric Souied,Ramin Tadayoni,Andrea Facsko,Agnes Kerénvi,Andras Papp,Alexis Tsorbatzoglou,Gabor Vogt,Yoreh Barak,Itay Chowers,Michaella Goldstein,Joel Hanhart,Haya Morori-Katz,Irit Rosenblatt,Alexander Rubowitz,Oren Tomkins Netzer,Francesco Bandello,Antonio Ciardella,Federico Ricci,Giovanni Staurenghi,Gianni Virgili,Kristine Baumane,Guna Laganovska,Signe Ozolina,Ilze Strautmane,Bartlomiej Kaluzny,Jerzy Mackiewicz,Marta Misiuk-Hoilo,Ewa Mrukwa-Kominek,Piotr Oleksy,Krystyna Raczynska,Tomasz Zarnowski,Alfredo Adan,Javier Araiz,Anna Boixadera,Alvaro Fernández-Vega,Alfredo Garcia Layana,Francisco Gomez-Ulla,Javier Montero,Jose Maria Ruiz Moreno,David Gilmour,Timothy Jackson,Sidath Liyanage,Luke Membrey,Geeta Menon,Niro Narendran,Sobha Sivaprasad,Daniel Alfaro,Andrew Antoszyk,Carl Baker,Ivan Batille,Brian Berger,David Boyer,William Bridges,Harold Brooks,David Brown,Margaret Chang,Daniel Chao,Sanford Chen,Courtney Crawford,Pravin Dugel,Alexander Eaton,David Eichenbaum,Jordana Fein,Leonard Feiner,Christina Flaxel,Frank Garber,Alan Gordon,Sunil Gupta,Curtis Haegedorn,George Hampton,Thomas Hanscom,Vrinda Hershberger,Peter Kaiser,Randy Katz,Arshad Khanani,Erik Kruger,Denis Marcus,Matthew Ohr,Sunil Patel,Joel Pearlman,Richard Pesavento,Dante Pieramici,John Pitcher,Jay Prensky,John Randolf,Carl Regillo,Steven Rose,Michael Samuel,Todd Schneiderman,Sumit Shah,Michael Singer,Nathan Steinle,Glenn Stoller,Alan Thach,John Thompson,Michael Varenhorst,Alan Wagner,Joseph Walker,John Wells,Jonathan Williams,Robert Wong,Charles Wykoff
DOI: https://doi.org/10.1016/j.ophtha.2023.02.001
IF: 14.277
2023-02-01
Ophthalmology
Abstract:PURPOSE: Neovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. Intravitreal injections of anti-VEGF-A drugs are the standard of care, but these do not inhibit VEGF-C and D, which may explain why many patients fail to respond fully. This trial aimed to test the safety and efficacy of OPT-302, a biologic inhibitor of VEGF-C and D, in combination with the anti-VEGF-A inhibitor ranibizumab.DESIGN: Dose-ranging, phase 2b, randomized, double-masked, sham-controlled trial.PARTICIPANTS: Participants with treatment-naive nAMD were enrolled from 109 sites across Europe, Israel, and the United States.METHODS: Participants were randomized to 6, 4-weekly, intravitreal injections of 0.5 mg OPT-302, 2.0 mg OPT-302, or sham, plus intravitreal 0.5 mg ranibizumab.MAIN OUTCOME MEASURES: The primary outcome was mean change in ETDRS best-corrected visual acuity (BCVA) at 24 weeks. Secondary outcomes (comparing baseline with week 24) were the proportion of participants gaining or losing ≥ 15 ETDRS BCVA letters; area under the ETDRS BCVA over time curve; change in spectral-domain OCT (SD-OCT) central subfield thickness; and change in intraretinal fluid and subretinal fluid on SD-OCT.RESULTS: Of 366 participants recruited from December 1, 2017, to November 30, 2018, 122, 123, and 121 were randomized to 0.5 mg OPT-302, 2.0 mg OPT-302, and sham, respectively. Mean (± standard deviation) visual acuity gain in the 2.0 mg OPT-302 group was significantly superior to sham (+14.2 ± 11.61 vs. +10.8 ± 11.52 letters; P = 0.01). The 0.5 mg OPT-302 group was not significantly different than the sham group (+9.44 ± 11.32 letters; P = 0.83). Compared with sham, the secondary BCVA outcomes favored the 2.0 mg OPT-302 group, with structural outcomes favoring both OPT-302 dosage groups. Adverse events (AEs) were similar across groups, with 16 (13.3%), 7 (5.6%), and 10 (8.3%) participants in the lower-dose, higher-dose, and sham groups, respectively, developing at least 1 serious AE. Two unrelated deaths both occurred in the sham arm.CONCLUSIONS: Significantly superior vision gain was observed with OPT-302 2.0 mg combination therapy, versus standard of care, with favorable safety (ClinicalTrials.gov identifier: NCT03345082).FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
ophthalmology